Today's edit page of The Indian Express has my column on the Indian drugs regulator's decision to ban pioglitazone, an anti-diabetes drug reportedly taken by 30 lakh patients. I have argued that India is paying for its historically casual attitude to pharmacovigilance or tracking drug safety. I have reproduced parts of the IE column below … Continue reading The pioglitazone ban : My column in The Indian Express
Apothecurry 